Please login to the form below
CROs
This page shows the latest CROs news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Ultomiris for NHS use in patients with rare blood disorders
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
Latest news
-
Sarepta Therapeutics’ DMD gene therapy shows early success
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
-
New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
Sarepta Therapeutics’ DMD gene therapy shows early success
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
More from news
Approximately 40 fully matching, plus 142 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
There are a number of adaptations that CROs and the wider healthcare industry must make to deliver on the promise of personalised medicines. ... This means that CROs need more sophisticated networks with volunteers, patient groups and the NHS in order to
-
Rare diseases: why they can be so difficult to identify
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
-
The lessons learned from COVID-19’s impact on oncology trials
Payments between drug sponsors, CROs and investigator sites are often a confusing process rife with delays.
-
A new era for UK-Japanese scientific research relations
Leading CROs have established dedicated Japanese patient recruitment and clinical teams in the capital to deliver these trials. ... UK CROs have a unique set of resources and expertise that support pharmaceutical companies in meeting the needs of the
-
Rare genetic diseases – what’s in store for 2021?
CROs and trial design • Early access and regulation • Value demonstration • Strategic communications.
How early-stage clinical research is facilitating the new wave of personalised medicines
Rare diseases: why they can be so difficult to identify
The lessons learned from COVID-19’s impact on oncology trials
A new era for UK-Japanese scientific research relations
Rare genetic diseases – what’s in store for 2021?
More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Dr Martine Dehlinger-Kremer becomes EUCROF president
Representing over 300 CROs across Europe, Dr Dehlinger-Kremer will be responsible for developing the foundation's educational activities and overseeing its plans for expansion.
-
XenoGesis appoints business development consultant
She has previously held director-level roles at US biotechs NovusLife and Cote Orphan, and US CROs Toxikon Corporation and XenoTech.
-
Cromsource expands executive leadership team
Dr McCall has nearly 25 years of experience in the pharmaceutical industry and has held senior leadership and advisory positions at CROs, private equity firms and non-profit organisations.
-
CROS NT names Mark Paul as senior VP of US operations
He joins from Veracity Logic. International contract research organisation CROS NT has appointed Mark Paul as senior vice president of its US operations. ... Andrew MacGarvey, CEO of CROS NT, added: “I am delighted to welcome Mark to our company.
-
PRC Clinical makes key management appointments
Commenting on Dowden's appointment, Taricco said: “Sue's proven track record working with sponsors and CROs gives PRC a unique advantage for customer satisfaction, quality assurance and successful trial management.”.
Dr Martine Dehlinger-Kremer becomes EUCROF president
XenoGesis appoints business development consultant
Cromsource expands executive leadership team
CROS NT names Mark Paul as senior VP of US operations
PRC Clinical makes key management appointments
More from appointments
Approximately 10 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
COUCH Health Engages Mark Duman as Chief Strategy Officer
COUCH Health works globally with pharma, biopharma, medical device companies and CROs, providing insights, patient recruitment, patient retention, and investigator site support. ... Through our work with pharma, biopharma, medical device companies and
-
COUCH Health Explores Lack of Ethnic Minorities in U.S. Clinical Trials
Through our work with pharma, biopharma, medical device companies and CROs, COUCH Health delivers a patient-first approach through patient insights, patient recruitment, patient retention, and investigator site support.
-
Veeda Clinical Research Pvt Ltd
We are one of the largest Independent CROs in India with a scientific edge, technical skills and better foresight for BA BE Studies &Clinical trials; with an objective of becoming a
-
August 2020: diversity and inclusion in clinical trials round-up
Improving diversity by starting within. Women of Color in Pharma (WOCIP) recently hosted a roundtable for 10 study sponsors and CROs about equality in biopharma.
-
Patients as partners: The future of clinical trial design?
Many CROs believe that adopting a more patient-centric design to their clinical trials will result in greater patient engagement, and more enrolled patients retained in the study. ... Currently, some CROs are being described as "patient-focused" but not
COUCH Health Engages Mark Duman as Chief Strategy Officer
COUCH Health Explores Lack of Ethnic Minorities in U.S. Clinical Trials
August 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Events Executive
-
Depending on Experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Eylea set to challenge Lucentis in UK after NICE recommendation
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
